Biotherapeutics – recombinant proteins, such as monoclonal antibodies – are highly complex molecules produced by fermentation. Unlike small molecule drugs they can contain numerous sites of heterogeneity as well as other impurities (which can arise from the manufacturing conditions or from the downstream processing). This presentation focuses on two different LC techniques for quantifying key impurities that are performed on the intact, non-denatured molecule.
Separation Science, in collaboration with Agilent Technologies, has developed an eSeminar covering the analysis of biotherapeutics and biosimilars.
This presentation is given by Andrew Coffey (Snr Applications Chemist, Agilent Technologies)
By attending this presentation you will learn about...
- Analysis of intact, non-denatured proteins
- Key considerations for accurate size exclusion chromatography
- Possibilities for extending the knowledge that can be derived from SEC separations
- Key considerations for robust ion exchange chromatography
- Possibilities for enabling MS detection
